合成生物学+多肽「修实生物」完成近亿元A轮融资

Core Insights - Xiushi Biopharmaceuticals (Nantong) Co., Ltd. has completed nearly 100 million yuan in Series A financing, led by existing shareholder Huatai Zijin, with additional investments from Shicui Capital, Jinding Capital, and Hunan Aichen [2][3] - Established in 2020, Xiushi Biopharmaceuticals focuses on synthetic biology and innovative peptide synthesis, becoming a national high-tech enterprise [2] - The company has developed a peptide innovation biosynthesis technology platform, overcoming industry bottlenecks in the biosynthesis of complex cyclic peptides, and is a leader in large-scale biosynthesis of complex short peptide drugs in China [2][3] Company Development - Xiushi Biopharmaceuticals has built an AI-enabled R&D center of over 5,000 square meters and a 13,000 square meter intelligent peptide drug production base, capable of flexible production from gram-level R&D samples to ton-level commercial products [3] - The company can meet both small-batch clinical sample needs and support large-scale commercial supply, positioning itself as a leading enterprise in the peptide biosynthesis field [3] - The successful completion of this financing round reflects continued recognition from existing investors and interest from new strategic investors, highlighting the company's growth potential [3]